

TRx Pharmaceuticals to be Acquired by Cerecor

Torreya Advised TRx Pharmaceuticals on Transaction

Research Triangle Park, NC and Baltimore, MD, November 30, 2017

TRx Pharmaceuticals, LLC (including subsidiary Zylera Pharmaceuticals, LLC), a pediatric specialty pharmaceutical company based in North Carolina, announced it has been acquired by Cerecor, Inc. The transaction includes an initial payment of \$27 million and an additional \$7 million in contingent payments upon achievement of certain commercial and regulatory milestones.

The acquisition of TRx provides Cerecor with a commercial franchise that will help to support the development of early stage orphan drug candidates for neurological disorders. The transaction also demonstrates a strategic shift toward pediatric healthcare for Cerecor.

Torreya acted as exclusive financial advisor to TRx Pharmaceuticals on this transaction. The transaction is the 23rd assignment on which Torreya has advised this year.

ABOUT TRX PHARMACEUTICALS, LLC

For more information about TRx, please see: www.zylera.com

ABOUT CERECOR, INC.

For more information about Cerecor, please see: www.cerecor.com

Deal Press Release



Torreya Contact

PETER GARRAMBONE

Partner | New York Office

pete.garrambone@torreya.com | 212.257.5808 | torreya.com

Torreya is a global advisory firm serving the life sciences industry. Please visit www.torreya.com for more information. Securities offered in the United States are offered through Financial West Group, Member FINRA/SIPC. Torreya Partners LLC and Financial West Group are unaffiliated entities. Torreya Partners LLC is a Delaware Limited Liability Company while Torreya Partners (Europe) LLP is a limited liability partnership, registered in England and Wales, registered number OC362930. Registered office: 119 The Hub, 300 Kensal Road, London W10 5BE. Torreya Partners (Europe) LLP is authorized and regulated by the Financial Conduct Authority. The information contained in the email and/or its attachments is confidential and/or privileged and is for the sole use of the intended recipient(s). If you are not the intended recipient, please notify the sender immediately by reply and immediately delete this message and all its attachments. Any review, use, reproduction, disclosure or dissemination of the message or any attachment by an unintended recipient is strictly prohibited. Neither this message nor any attachment is intended as or should be construed as an offer, solicitation or recommendation to buy or sell any security or other financial instrument. This communication is for informational purposes only. All investments involve risks including loss of principal invested. Past performance does not guarantee future results or success. Torreya Capital and its representatives do not provide tax or legal advice and each tax and financial situation is unique. Investors should consult their tax and/or legal advisor for advice and information concerning their particular situation.